Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, provides an overview of current antibody-based therapies used to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). They can be categorized into CD20-targeting bispecifics, including glofitamab and epcoritamab, and antibody-drug conjugates, including polatuzumab vedotin and loncastuximab tesirine. They are most frequently used in the third-line setting, but ongoing trials are exploring their potential use in frontline settings and in combination with other drug modalities. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть